We are proud to present the return of our 6th annual
Cancer Vaccines conference to London in September 2017. The use of therapeutic
cancer vaccines in combination with other therapies remains the most effective method of cancer treatment available. With diversification of cancer vaccines propelling growth and innovation in the
cancer vaccines industry, approaches to combatting cancer and enhancing vaccine efficacy are developing and improving year on year.
With particular focus on autologous tumour cell immunotherapy, combinatorial approaches including immune checkpoint inhibitors and IDO inhibitors and clinical trials, our 6th annual
Cancer Vaccines conference will provide the perfect platform to highlight emerging strategies in
cancer vaccines, and overcome the challenges facing development of successful vaccines for what is a competitive and important market.
This event will bring together industry leaders to share ideas and experience of developing successful
cancer vaccines. 16+ industry led presentations and focus on the latest advances in personalised cancer treatments make this a leading event for the
cancer vaccines industry.
Benefits of Attending
- Exploring personalising cancer vaccines, characterising and applying the outside in approach in cancer vaccine development
- Maximising the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors
- Benefit from in depth case study examples showcasing peptide, neoantigen and MHC based vaccine development
- Assessing the emerging pipeline of preclinical data for preventative cancer vaccines
Plus One Intersctive Half-Day Pre-Conference Workshop | Tuesday 26th September 2017
Biomarkers of immune responseWorkshop Leaders: Rose-Ann Padua, Research Director, INSERM | Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM
Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou | Sharam Kordasti, Honorary Senior Lecturer, Department of Haematological Medicine, Kings College London
12.30 - 16.00
Speakers
- Agnete Fredriksen, CSO, Vaccibody AS
- Alfredo Nicosia, CEO, Nouscom srl / Reithera srl
- Angus Dalgleish, Research Director, Onyvax Ltd.
- David Giljohann, CEO, Exicure Inc.
- Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
- Fatema Legrand, Senior Clinical Scientist , Genentech
- Jonathan Zalevsky, Senior Vice President Biology & Preclinical Development, Nektar Therapeutics
- Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, Merck Sharp & Dohme Limited
- Linda Powers, CEO, Northwest Biotherapeutics Inc
- Ludwig Heesen, Project Manager, BioNTech AG
- Mads Hald Andersen, Vice-Director, Professor, Co-Founder, ccit-denmark
- Rose-Ann Padua, Director of Research, INSERM
- Sofie Pattijn, Chief Technology Officer, ImmunXperts
- Stephanie McArdle, Senior Research Scientist, Nottingham Trent University
- Sune Justesen, CSO, Immunitrack Aps
- Zahra Jawad, Group Leader in Discovery Technology, Agenus
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
Copthorne Tara Hotel
Scarsdale Pl, Kensington, W8 5SY
London, UK
Who should attend
Directors, senior scientists, project leaders, research directors of:
- Immuno-oncology
- vaccine development
- oncology
- molecular medicine
- immunobiology
Venue
Copthorne Tara HotelScarsdale Place, Kensington
London, United Kingdom
